<DOC>
	<DOCNO>NCT02182544</DOCNO>
	<brief_summary>Study investigate efficacy WAL801CL Dry Syrup comparison ketotifen fumarate pediatric perennial allergic rhinitis evaluate safety WAL801CL Dry Syrup compare ketotifen fumarate confirm appropriateness dosage WAL801 Dry Syrup .</brief_summary>
	<brief_title>WAL801CL ( Epinastine Hydrochloride ) Dry Syrup Paediatric Perennial Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Ketotifen</mesh_term>
	<mesh_term>Epinastine</mesh_term>
	<criteria>15 year age young Body weight 14 kg Typical symptom perennial allergic rhinitis , within 2 high score serum specific immunoglobulin E ( IgE ) cause house dust ( HD ) mite data obtain past one year `` Moderate '' `` Severe '' Allergic Rhinitis Severity Classification observation period The Patient Diary enter patient parent Outpatients Absolute necessity treatment drug may affect evaluation effect investigational drug ( e.g. , antihistamine , antiallergics , steroid , vasopressor ) . Patients treat follow drug , however , may include Intal® Oral Inhalation Any eye drop Zaditen® Eye Drop External preparation ( liniment , poultice ) Initiation desensitisation therapy within past 6 month Onset acute upper respiratory inflammation observation period Nasal disease , acute chronic rhinitis , nasal polyp , hypertrophic rhinitis , septal deviation* , sinusitis* , hypertrophy adenoid* , degree disease affect evaluation effect test drug ( * : Xray examination conduct necessary ) That pollen ( cider , ragweed , Japanese cypress , orchard grass , etc . ) double antigen , study conduct season airborne pollen , symptom may exacerbate pollen Present past history convulsive disease , epilepsy ( convulsion threshold value may decrease comparator drug , ketotifen fumarate ) Clinically significant abnormal change laboratory measurement , thus judgement patient ineligible inclusion study ; however , patient judge fall Grade 2 accord MHW ( Ministry health welfare ) Adverse Reaction Severity Classification Criteria , patient exclude study Clinically significant renal , hepatic cardiac disease , complication , thus judgement patient ineligible inclusion study ; however , patient judge fall Grade 2 accord MHW Adverse Reaction Severity Classification Criteria , patient exclude study Past history drug allergy 1 month , 6 time long half life investigational drug 1 month , pass since participation clinical trial study , time initiation study Judgement Principal Investigator Investigator patient ineligible inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>